Searched for
GLAXOSMITHKLINE BIOLOGICALS
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...- Budget 2026 gives biologics & biosimilars a major policy boostIndia is set to become a global biopharmaceutical manufacturing hub. Finance Minister Nirmala Sitharaman announced a dedicated ₹10,000 cror...
- Biocon Biologics announces top leadership appointmentsBiocon Biologics Ltd has made several key leadership appointments, including appointing Rhonda Duffy as Chief Operating Officer and Sandeep...
- Samsung Biologics unveils $897 mln manufacturing deals for PfizerSouth Korea's Samsung Biologics announced on Tuesday two deals with Pfizer worth a combined $897 million to manufacture products for the U....
- CCI approves BC Asia Investments' stake acquisition in IIFL Wealth ManagementBC Asia Investments X Ltd is indirectly held by Bain Capital Investors LLC (Bain Private Equity), Bain Capital Credit Member LLC and Bain C...
- Cipla, Kemwell Biopharma join hands to develop biosimilarsUnder the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product develo...
- GSK to fund doctoral programs at Regional Centre for BiotechnologyStudents with a master’s degree in biostatistics, maths, statistics and bioinformatics can apply, and will have to take an aptitude test an...
- Suresh Subramanian to head Biocon's branded formulations bizSuresh has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline,...
- Rx: Make All Clinical Trial Data PublicShould drug companies make clinical trials data public?
- GSK in 50:50 JV with Biological E for developing paediatric vaccineThe vaccine would enable fewer injections for children thereby improving compliance in immunisation schedules.
- Four growth drivers beyond patent for pharma companies like Sun Pharma, SanofiIt is not just Big Pharma that has to prepare for life after the 'patent cliff'' patent expiries on a slew of blockbuster drugs.
- GlaxoSmithKline Biologicals in talks to buy BE's vaccine divisionThis division produces and markets a range of paediatric and adult vaccines and has a sizeable market share in the Indian vaccine market.
- DRL seeks USFDA help to make cancer drug cloneUS-based biotech firm Celgene, the innovator, has declined to make the drug samples available to DRL for bio-equivalence studies.
- Pharma MNCs want to take a shot at India’s vaccine marketMultinational pharmaceutical companies are now increasingly looking at the Indian vaccine market in a big way. MSD Pharmaceuticals, GlaxoSm...
- Cellworks' tech to eliminate testing of drugs on humansIn Cellworks' model, the effect of a drug on the specific disease can be seen exactly as it would happen in a human body, thereby eliminati...
- GlaxoSmithKline wins European nod for bird flu vaccinesBritish pharmaceuticals giant GlaxoSmithKline has won European recommendations for two vaccines aimed at combatting a potential bird flu pa...
- Diabetes drug may increase chances of osteoporosisThe popular diabetes drug marketed as Avandia may increase bone thinning, a discovery that could help explain why diabetics can have an inc...
- Zenotech likely to make a pref allotment to RanbaxyZenotech Laboratories will make a preferential allotment of its shares to Ranbaxy Laboratories. In a notice to the BSE, the company said th...
- Ranbaxy to buy 10% in Zenotech for Rs 20 crRanbaxy Laboratories, is close to picking up a 10% stake in Hyderabad-based Zenotech Laboratories for about Rs 20 crore as it moves to plug...
- LVPs can be produced under loan licenceThe government has cleared a proposal to allow manufacture of large volume parenterals under loan licences.
Load More
